CLIMB BIO, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
CLIMB BIO, INC. (CLYM) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $27.99 million as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Notes
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2025-05-14
- 2025-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $27.99M.
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $36.45M.
- 2024-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $2.94M.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $8.20M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2025-03-31 | $27.99M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $36.45M 10-Q · filed 2025-05-14 |
| 2024-09-30 | $2.94M 10-Q · filed 2024-11-12 |
| 2023-12-31 | $8.20M 10-K · filed 2025-03-25 |
| 2023-09-30 | $29.70M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $51.22M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $20.76M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $28.48M 10-K · filed 2024-03-28 |
| 2022-09-30 | $41.93M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $61.11M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $64.33M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $64.11M 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |